Survivin expression in endometrial carcinoma: A tissue microarray study with correlation with PTEN and STAT-3

International Journal of Gynecological Pathology

Volumn 24, Issue 3, 2005, Pages 247-253

  Pallares, Judit ^a,b,c   Martínez Guitarte, Jose Luis ^a   Dolcet, Xavier ^a   Llobet, David ^a   Rue, Montserrat ^a   Palacios, José ^a,b,c   Prat, Jaime ^a,b,c   Matias Guiu, Xavier ^a  

^a HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Apoptosis; Endometrial carcinoma; Molecular pathology; Survivin; Tissue microarray

Indexed keywords

BETA CATENIN; CELL MARKER; CELL PROTEIN; CYTOKERATIN; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN CTNNB 1; PROTEIN KINASE B; PROTEIN P53; STAT3 PROTEIN; SURVIVIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DEATH; CELL DIVISION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY;

APOPTOSIS; BETA CATENIN; CARCINOMA; CELL GROWTH PROCESSES; CYTOSKELETAL PROTEINS; DNA-BINDING PROTEINS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PHOSPHORIC MONOESTER HYDROLASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TISSUE ARRAY ANALYSIS; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 21244497846     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pgp.0000163849.37129.d4     Document Type: Article

References (37)

1. Bockman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-7.
2. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. The frequency of p53, K-RAS mutations, and microsatellite instability differs in uterine endometrioid and serious carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000;88:814-824.
3. Matias-Guiu X, Catasus LL, Bussaglia E, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001; 32:569-77.
4. Bussaglia E, del Rio E, Matias-Guiu X, et al. PTEN mutations in endometrial carcinoma: A molecular and clinicopathologic analysis of 38 cases. Hum Pathol 2000;31:312-7.
5. Moreno-Bueno G, Sánchez-Estevez C, Cassia R, et al. Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res 2003;63: 5697-702.
6. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003;22:8581-9.
7. Allied DC. Survivin and apoptosis control. Adv Cancer Res 2003; 88:31-52.
8. Takai N, Miyazaki T, Nishida M, et al. Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma. Cancer Lett 2002;184:105-16.
9. Kanda N, Seno H, Konda Y, et al. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene 2004;23:4921-9.
10. Lagarda H, Catasus L, Arguelles R, et al. K-ras mutations in endometrial carcinomas with microsatellite instability. J Pathol 2001;32: 569-77.
11. Palacios J, Moreno-Bueno G, Catasus LL, et al. Beta and ganima-catenin expression in endometrial carcinoma: relationship with clinicopathological features and microsatellite instability. Virchows Arch 2001;438:464-9.
12. Machin P, Catasus L, Pons C, et al. CTNNB1 mutations and beta-catenin expression in endometrial carcinomas. Hum Pathol 2002; 33:206-12.
13. Moreno-Bueno G, Hardisson D, Sanchez C, et al. Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene 2002;14:7981-90.
14. Salvesen G, Duckett CS. IAP proteins: blocking the road to death's door. Nature 2002;3:401-10.
15. Altieri DC. Survivin in apoptosis control and cell cycle regulation in cancer. Prog Cell Cycle Res 2003;5:447-52.
16. Schlette EJ, Medeiros LJ, Goy A, et al. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol 2004;22:1682-8.
17. Tran J, Master Z, Yu JL, et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 2002;99:4349-54.
18. Zhang T, Otevrel T, Gad Z, et al. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 2001;62:8664-7.
19. Papapetropoulos A, Fulton D, Mahboudi K, et al. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 2000;275:9102-5.
20. Di Cristofano A, Pandolli PP. The multiple roles of PTEN in tumor suppression. Cell 2000;100:387-90.
21. Yamada KM, Araki M. Tumor supressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J Cell Sci 2001;114: 2375-82.
22. Kanamori Y, Kigawa J, Itamochi H, et al. PTEN expression is associated with prognosis for patients with advanced endometrial carcinoma undergoing postoperative chemotherapy. Int J Cancer 2002;100:686-9.
23. Terakawa N, Kanamori Y, Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr Relat Cancer 2003;10: 203-8.
24. Salvesen HB, Stefansson I, Kalvenes MB, et al. Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma. Cancer 2003;94:2185-91.
25. Peiro G, Lohse P, Mayr D, et al. Insulin-like growth factor-1 receptor and PTEN protein expression in endometrial carcinoma. Correlation with bax and bcl-2 expression, microsatellite instability status, and outcome. Am J Clin Pathol 2003;20:78-85.
26. Kimura F, Watanabe J, Hata H, et al. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus. J Cancer Res Clin Oncol 2003;130: 161-8.
27. Nelen MR, van Staveren WCG, Peeters EAJ, et al. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet 1997;6:1383-7.
28. Marsh DJ, Coulon V, Lunetta KL, et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 1998;7:507-15.
29. Marsh DJ, Dahia PLM, Caron S, et al. Germline mutations in Cowden syndrome-like families. J Med Genet 1998;35:881-5.
30. Kong D, Suzuki A, Zou TT, et al. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet 1997;17:143-4.
31. Mutter GL, Ince TA, Baak JPA, et al. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res 2001;61:4311-14.
32. Shuai K, Liu B. Regulation of Jak-STAT signaling in the immune system. Nature 2003;3:900-11.
33. Gamero AM, Young HA, Wiltrout RH. Inactivation of STAT3 in tumor cells: releasing a brake on immune responses against cancer? Cancer Cell 2004;5:111-112.
34. Rivat C, De Wever O, Bruyneel E, et al. Disruption of STAT3 signaling leads to tumor cell invasion through alterations of homotipic cell-cell adhesion complexes. Oncogene 2004;23: 3317-27.
35. Bromberg J. Signal transducers and activators of transcription as regulators of growth, apoptosis and breast development. Breast Cancer Res 2000;2:86-90.
36. Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by STAT-3 signaling in tumor cells. Nat Med 2004;10:48-54.
37. de Miguel F, Lee SO, Onate SA, et al. STAT3 enhances transactivation of steroid hormone receptors. Nucl Recept 2003;1:3-10.